Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using purified recombinant reverse transcriptase from a zidovudine-susceptible and -resistant pair of clinical isolates of human immunodeficiency virus type 1. The zidovudine-resistant isolate exhibited low-level cross-resistance to both stavudine and lamivudine in drug susceptibility assays. Enzyme from the resistant isolate demonstrated reduced inhibition by zidovudine triphosphate and stavudine triphosphate and, to a lesser extent, lamivudine triphosphate. These findings provide additional evidence at the viral and enzyme level for cross-resistance between zidovudine and stavudine, and they suggest a possible effect of zidovudine resistance on susceptibility to lamivudine.
demonstrate [2] . Reports from our laboratory and others provide evidence that stavudine selects for the same resistance mutations as does zidovudine and that the presence of zidovudine resistance mutations confers cross-resistance to stavudine [3] [4] [5] . High-level resistance to lamivudine is conferred by the M184V mutation, but low-level resistance can be conferred by mutations at codons 44 and 118 [6] .
Previous studies of zidovudine resistance generally have relied on RT derived from a laboratory-adapted isolate (Hxb2) molecularly engineered to carry one or more zidovudine resistance mutations. Such molecularly constructed viruses may differ significantly from viruses selected in response to drug pressure in vivo. In most cases, significant resistance to zidovudine triphosphate (TP) at the enzyme level has not been observed [7] . Because the expression of zidovudine resistance may vary in different HIV-1 genetic backgrounds, zidovudine-TP inhibition of purified RT derived from a pair of zidovudinesusceptible and -resistant clinical isolates was studied. In addition, inhibition of RT from these isolates by stavudine-TP and lamivudine-TP was studied, to determine the extent of cross-resistance to these nucleoside analogues at the enzyme level.
Materials and Methods
HIV-1 strains 18A and 18C are paired zidovudine-sensitive and -resistant isolates, respectively, that were obtained from the same patient before and after treatment with zidovudine monotherapy [8] . The isolates were provided by D. Richman (University of California-San Diego) through the National Institutes of Health AIDS Research and Reference Reagent Repository. Susceptibility of viruses expressing 18A and 18C RT was tested by a standard pe-ripheral blood mononuclear cell (PBMC) assay [9] or by a recombinant virus assay (PhenoSense; ViroLogic) [10] .
The entire RT-coding region of pol was amplified by nested polymerase chain reaction from PBMC infected with strains 18A or 18C in vitro and was cloned into the Escherichia coli expression plasmid pRT581 under control of the lacZ promoter [11] . Stop codons were inserted after nucleotide 4210 (corresponding to RT codon 560 in the HXB2 sequence) or after nucleotide 3853 (codon 440 of the HXB2 sequence), to generate plasmids expressing p66 and p51 subunits, respectively. The RT coding sequence with a stop signal at codon 441 was then subcloned into pQE9 (Qiagen), thereby inserting a His 6 -tag at the amino terminus of p51 to facilitate purification. Nucleotide sequencing confirmed the presence of zidovudine resistance mutations 41L, 67N, 70R, 215Y, and 219Q in the 18C RT and the absence of adventitious mutations. The sequences of 18A and 18C RT have been deposited in GenBank (accession nos. AY044639 and AY044640).
To prepare purified RT heterodimer, p51 and p66 subunits were expressed separately in E. coli cells transfected with the relevant plasmid, and the cells were induced to express RT by isopropyl thio-b-D-galactoside. Cultures were mixed, and the cells were collected by centrifugation and lysed into buffer containing 50 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl, 10 mM imidazole, 100 mM phenylmethylsulfonyl fluoride, 10 mM leupeptin, and 10 mM aprotinin. Lysates were incubated at 4ЊC with gentle stirring in the presence of 10 mM MgCl 2 for 48 h, to allow heterodimer formation. Lysates then were applied to a Ni 2ϩ -NTI agarose column, eluted with 250 mM imidazole buffer, dialyzed, and applied onto a HiTrap SP column (Pharmacia Biotech) to separate the dimeric fraction from excess His 6 -p51. After elution with a 30-500-mM NaCl gradient, samples containing stoichiometric amounts of p66 and p51 were pooled, dialyzed against 50% glycerol, and stored at Ϫ70ЊC. Preparations of heterodimer were 195% pure and contained stoichiometric amounts of the p66 and p51 subunits, as determined by SDS-PAGE (data not shown).
Steady-state kinetics of RNA-dependent DNA polymerase activity were determined by a standard [ 3 H]thymidine incorporation assay, using a preannealed heteropolymeric RNA/DNA template: primer in the absence or presence of zidovudine-TP, stavudine-TP, or lamivudine-TP. Zidovudine and stavudine were purchased from Sigma, and lamivudine was provided by GlaxoSmithKline. Stavudine-TP was provided by R. Lanier (GlaxoSmithKline) or was synthesized and purified by high-pressure liquid chromatography by Sierra Bioresearch. Lamivudine-TP was obtained from Sierra Bioresearch.
To prepare the heteropolymeric template:primer complex, an RNA transcript of nt ϩ1 to ϩ513 of the HIV-1 5 long terminal repeat (contained in pLL111) was used as template, and an 18-mer DNA oligonucleotide that is complementary to the primer binding site on the HIV-1 genome (5 -GTC CCT GTT CGG GCG CCA-3 ) was used as primer [12] . Reaction mixtures containing templateprimer complex at 20 nM, Tris-HCl (pH 8.0) at 50 mM, MgCl 2 at 10 mM, dNTPs at 80-120 mM, 0.5 mCi of [ 3 H]dTTP, and RT at 20 nM, in a final volume of 50 mL, were incubated at 37ЊC for variable times. Reactions were quenched by adding 0.2 M sodium pyrophosphate (PPi) plus 10% trichloroacetic acid and were incubated on ice, and the precipitated nucleic acid was collected onto GFC filters (Whatman) and analyzed by liquid scintillation counting.
Kinetic constants (V max and K M ) were determined by time-course experiments in which reactions were sampled at intervals of up to 80 s, using dTTP at serial 2-fold dilutions with a range of 5-80 mM (V max is the maximum reaction rate in the presence of substrate excess, and K M can be defined as the substrate concentration at which the reaction rate is half maximal). Initial rate data were fitted to double reciprocal plots (i.e., 1/rate vs. 1/dTTP concentration), and 1/V max and 1/K M were determined from the y and x intercepts, respectively. The IC 50 values for nucleoside TPs were determined in assays using serial half-log 10 dilutions of inhibitor, with a range of 0.10-100 mM; reactions were incubated for 10 min at 37ЊC and were analyzed as described above. The IC 50 values were calculated by the median-effect equation [13] .
Results
In the PBMC assay, strain 18C exhibited 400-fold resistance to zidovudine (IC 50 figure 1 ). Recombinant viruses expressing 18A RT had IC 50 values for zidovudine, stavudine, and lamivudine that were 0.7-fold, 1.0-fold, and 1.5-fold those of the control, respectively (differences of 11.7-fold for stavudine and 12.5-fold for zidovudine and lamivudine are considered significant in this assay.)
In the absence of inhibitor, purified RT heterodimer derived from strains 18A and 18C showed similar specific activities ( U mg protein Ϫ1 and U ). Likewise, V max for dTTP incorporation P p .294 was similar to that for 18A and 18C RT ( and 10.21 ‫ע‬ 0.90 pmol/min, respectively; ). 11.58 ‫ע‬ 0.33 P p .179 As compared with wild-type (18A) enzyme, RT from strain 18C demonstrated a 9.5-fold increase in IC 50 for zidovudine-TP ( ) and a 10.1-fold increase in IC 50 for stavudine-TP P ! .001 ( ). The IC 50 for lamivudine-TP of 18C RT increased P p .004 2.6-fold, compared with 18A RT ( ). Because recent P p .001 reports suggest that pyrophosphorolysis contributes to the mechanism of zidovudine resistance, the effect of PPi on inhibition of RT activity by nucleoside analogue TPs was examined. The presence of PPi at 150 mM increased the IC 50 of zidovudine-TP for 18A and 18C RT 2-4-fold (table 1). How- ever, the presence of PPi did not significantly increase the IC 50 of stavudine-TP for these enzymes.
Discussion
Although strain 18C was one of the first zidovudine-resistant HIV-1 isolates to be reported [8] , only limited studies using purified RT derived from this strain and the pretreatment isolate 18A have been done. The finding of decreased inhibition by zidovudine-TP of purified recombinant RT from the zidovudineresistant strain 18C differs from those of other studies, which failed to find such differences with RTs derived from zidovudineresistant Hxb2 variants [7] . It is possible that sequence variation at sites not known to be involved in zidovudine resistance partly accounts for this differences. For example, RT from strains 18A and 18C differs from Hxb2 RT at 13 codons not known to be related to zidovudine resistance (authors' unpublished observations). It is also possible that differences in the methods used for preparing purified RT heterodimer could account for differences between our results and those observed in earlier studies.
Cross-resistance between zidovudine and stavudine in strain 18C was found by use of a standard PBMC-based drug susceptibility assay and a recombinant virus assay. In addition, recombinant RT heterodimer derived from strain 18C showed cross-resistance to zidovudine-TP and stavudine-TP. Wild-type and mutant enzymes had similar specific activities and similarK M and V max values for dTTP, suggesting that the observed cross-resistance at the enzyme level was not an artifact of the enzyme preparation. These results are consistent with those of other studies that demonstrate selection by stavudine of mutations associated with zidovudine resistance [3, 5] . These results also are consistent with results that demonstrate reduced clinical response to stavudine in patients who harbor zidovudine-resistant HIV-1 [4] . They also provide additional evidence for cross-resistance between zidovudine and stavudine at the enzyme level.
Modest cross-resistance to lamivudine and lamivudine-TP was also observed in the drug susceptibility and enzyme assays, respectively. Mutations at codons 44 and 118, which are selected by zidovudine and can confer low-level cross-resistance to lamivudine [6] , were absent in strain 18C. Site-directed mutagenesis studies are needed to determine whether the 208Y substitution, which is present in strain 18C but not 18A, contributes to the observed phenotype. Additional studies with purified RT from other clinical isolates with high-level zidovudine resistance also are needed, to determine whether these findings can be generalized. HIV-1 RT can catalyze the removal of the terminal nucleotide monophosphate from the growing DNA chain in the presence of physiologic concentrations of PPi [14] . Enzymes carrying the 67N/70R mutations show a 4-fold increase in sensitivity to inhibition by PPi and an increased rate of removal of the terminal zidovudine monophosphate by PPi. Purified RT from a zidovudine-resistant derivative of HXB2 (41L/67N/70R/215Y) demonstrates a significant increase in IC 50 for zidovudine-TP, compared with wild-type, when tested in the presence of ATP or PPi, but it shows no difference from wild-type enzyme in their absence [15] . In our experiments, PPi increased the IC 50 of zidovudine-TP for wild-type and mutant enzyme to a similar extent (3-fold and 2-fold, respectively). PPi did not increase the IC 50 for stavudine-TP in either the wild-type or mutant enzyme. More detailed mechanistic studies are needed to determine the role of pyrophosphorolysis and primer unblocking in resistance to zidovudine and stavudine in strain 18C.
In conclusion, steady-state kinetic studies of purified recombinant RT heterodimer derived from paired wild-type and zidovudine-resistant clinical isolates showed inhibition kinetics for zidovudine-TP, stavudine-TP, and lamivudine-TP that mirrored the phenotype of viruses expressing these RTs. The observed viral and biochemical phenotypes support the concepts that high-level zidovudine resistance confers at least partial cross-resistance to other nucleoside analogues and that crossresistance within the nucleoside analogue class of HIV-1 inhibitors is more general than previously believed.
